ReviewCureus2025
Risk Factors Contributing to Hepatitis C Virus Infection in Kashmir: A Meta-Analysis.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis C virus (HCV) infection is a growing public health concern in Kashmir. This meta-analysis identifies and quantifies key risk factors associated with HCV in the region to guide public health interventions. A systematic review of six studies conducted in Jammu and Kashmir analyzed data from various population groups. The overall HCV prevalence in a general population survey was 38.37%, with injection drug use and dental procedures identified as major risk factors. Among hospitalized jaundiced children, 2% tested HCV-positive, both linked to chronic liver disease. A large retrospective study on blood donors (n = 97,427) found a low HCV prevalence (0.20%), with no cases among repeat voluntary donors, reinforcing the safety of voluntary blood donation. High-risk groups, including intravenous drug users (42.16%) and people who inject drugs (PWIDs) (10%), exhibited significantly higher HCV prevalence. Most PWIDs were young (69% aged 16-25 years) and from urban areas (73.5%). Financial constraints hindered treatment access for 17% of infected individuals. A molecular epidemiology study in Jammu reported 8.33% HCV prevalence, with genotype 3 being the most common strain. This meta-analysis highlights unsafe medical practices, intravenous drug use, and unregulated body modifications as major contributors to HCV transmission in Kashmir. Urgent interventions, including harm reduction programs, improved healthcare practices, and public awareness campaigns, are necessary to curb HCV spread in the region. Strengthening healthcare infrastructure and ensuring accessible treatment can significantly reduce HCV-related morbidity and mortality in Kashmir.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.